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and cardiometabolic risk factors and subclinical
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Background: The published literature regarding the relationships between retinol-binding protein 4 (RBP4) and
cardiometabolic risk factors and subclinical atherosclerosis is conflicting, likely due, in part, to limitations of
frequently used RBP4 assays. Prior large studies have not utilized the gold-standard western blot analysis of RBP4
levels.
Methods: Full-length serum RBP4 levels were measured by western blot in 709 postmenopausal women screened
for the Kronos Early Estrogen Prevention Study. Cross-sectional analyses related RBP4 levels to cardiometabolic risk
factors, carotid artery intima-media thickness (CIMT), and coronary artery calcification (CAC).
Results: The mean age of women was 52.9 (± 2.6) years, and the median RBP4 level was 49.0 (interquartile range
36.9-61.5) μg/mL. Higher RBP4 levels were weakly associated with higher triglycerides (age, race, and smoking-
adjusted partial Spearman correlation coefficient = 0.10; P= 0.01), but were unrelated to blood pressure, cholesterol,
C-reactive protein, glucose, insulin, and CIMT levels (all partial Spearman correlation coefficients ≤0.06, P> 0.05).
Results suggested a curvilinear association between RBP4 levels and CAC, with women in the bottom and upper
quartiles of RBP4 having higher odds of CAC (odds ratio [95% confidence interval] 2.10 [1.07-4.09], 2.00 [1.02-3.92],
1.64 [0.82-3.27] for the 1st, 3rd, and 4th RBP4 quartiles vs. the 2nd quartile). However, a squared RBP4 term in
regression modeling was non-significant (P= 0.10).
Conclusions: In these healthy, recently postmenopausal women, higher RBP4 levels were weakly associated with
elevations in triglycerides and with CAC, but not with other risk factors or CIMT. These data using the gold standard
of RBP4 methodology only weakly support the possibility that perturbations in RBP4 homeostasis may be an
additional risk factor for subclinical coronary atherosclerosis.
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Obesity, a worldwide epidemic, is associated with a dra-
matic increase in the prevalence of type 2 diabetes, and
has been associated with cardiovascular disease (CVD)
morbidity and mortality [1-3]. Retinol-binding protein 4
(RBP4), which is released primarily by the liver, has
recently been shown to be released by adipose tissue as
well [4]. RBP4 down-regulates the glucose transporter
GLUT4 [5-7], which acts as the rate-limiting step in
insulin-activated glucose transport across both muscle and
adipocyte membranes [6]. In humans, circulating RBP4
levels have been shown to be negatively correlated with
levels of insulin sensitivity, and to be higher among indivi-
duals with obesity and type 2 diabetes, as well as among
those with adverse CVD risk factor profiles or metabolic
syndrome, frequently independent of body size [6-14].
However, conflicting data also exist [9,15-17]. Discrepan-
cies in published RBP4 data may relate to complications of
the RBP4 assay methodology [18], which this study has
striven to overcome with western blot analysis.
The purpose of the current study was to examine the
associations of RBP4 with both standard CVD risk factors
as well as subclinical atherosclerosis in healthy mid-life
women screened for the Kronos Early Estrogen Prevention
Study (KEEPS). Western blot, the gold standard analytic
technique for RBP4 [18], was used for RBP4 analysis
to overcome problems associated with other analytical
techniques.
Methods
Study population
The current cross-sectional analyses utilize data from the
KEEPS, a randomized, placebo-controlled, double-blinded,
prospective trial of the effects of menopausal hormone
therapy on the progression of subclinical atherosclerosis in
recently menopausal women. KEEPS is a multi-center trial
with 9 centers (University of Utah, University of California
at San Francisco; Brigham and Women’s Hospital; Mayo
Clinic, Rochester; Columbia University College of Physi-
cians and Surgeons;VA/ University of Washington; Yale
University; Montefiore Medical Center; Kronos Longevity
Research Institute). KEEPS inclusion criteria were age
42–58 years, at least 6 months but no more than
36 months of amenorrhea and last spontaneous menses
occurring after age 40, FSH values ≥35 ng/ml and/or
estradiol levels <35 pg/ml, and good general health.
Women reporting use of estrogen- or progestin-containing
medication (oral contraceptive or hormone replacement),
selective estrogen receptor modulators (SERMs), or
medications with significant estrogenic activity, such as
isoflavones, in the prior 3 months, a history of clinical
CVD, current heavy smoking (greater than one half
pack per day), a body mass index (BMI) ≥35 kg/m2, LDL
cholesterol > 190 mg/dL or triglycerides >400 mg/dL,diabetes, uncontrolled hypertension, or with moderate
subclinical CVD, defined as a coronary artery calcium
(CAC) score ≥50 Agatston units, were ineligible for
randomization. Women meeting eligibility criteria were
randomized to one of three treatment groups: oral
conjugated equine estrogen (Premarin, 0.45 mg/day) with
oral micronized progesterone (12 days per month), trans-
dermal 17β-estradiol (via skin patch, Climara, 50 μg/day)
with oral micronized progesterone (12 days per month),
and one daily placebo group (inactive pill/patch) with pla-
cebo micronized progesterone (12 days per month). The
current analyses utilize data from the screening and base-
line KEEPS visit, prior to randomization and receipt of any
estrogen therapy or placebo. A total of 1,046 women were
screened between July 2005 to June 2008, with 775 of
them passing earlier screening components and eventually
receiving a CT scan for the purposes of confirming CAC
Agatston score eligibility. Of these, 66 women were miss-
ing RBP4 data, leaving 709 women for the current ana-
lyses. The institutional review boards of the participating
institutions approved this study, and all women signed
informed consent.
Blood measures
All blood specimens were collected following an overnight
fast, then frozen at −70°C on site until they were either
processed locally, or sent to the Kronos Science Labora-
tory (Phoenix, AZ, USA) for storage or assays. Complete
blood count and chemistry panel were performed at the
clinical laboratories at each recruiting center. C-reactive
protein (CRP) and insulin were assayed by DPC Immulite
2000 (Diagnostic Products Corporation, Los Angeles, CA).
RBP4 in human serum was measured by quantitative
western blotting [18]. Briefly, native RBP4 purified from
human serum (Hytest) was used for assay calibration.
Each gel (18 wells) contained a molecular weight marker,
five concentrations of RBP4 standards, four low and high
levels of controls made by human serum, and eight
patient samples. RBP4 standards were placed in the same
position at the center of each gel. RBP4 standard solu-
tions of 15, 30, 60, 120, and 240 μg/ml were prepared in
10 mM phosphate buffer with 150 mM NaCl (pH 7.4).
Standards, controls, and patient samples were diluted
1:200 in SDS-PAGE buffer and boiled for 5 min. 25 μl
of diluted standards, controls, patient samples, and a
molecular weight marker (Bio-Rad precision plus protein
standards kaleidoscope) were then electrophoresed on
18% Criterion Tris-glycine SDS-PAGE gels ( BioRad)
and transferred to nitrocellulose. Western blotting was
performed with 5% non-fat dry milk in tris-buffered
saline with 1% of detergent as a blocking agent. Blots were
incubated overnight at 4°C with rabbit anti-human RBP
primary antibody (DAKO) diluted 1:1,000 and for 1 h at
room temperature with ECL horseradish-peroxidase-
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Bands were detected by enzymatic chemiluminescence and
quantified using the Kodak Gel Logic 100 Digital Imaging
System and Carestream Molecular Imaging Software. A
single band for RBP4 migrated at about 21 kDa. Exponen-
tial curves were used to fit the RBP4 standards for each
individual gel and calculate concentrations in patient
samples. The gel to gel variation (inter precision) was
monitored by two levels of controls with CV less than
15%. The control results of each gel were reviewed to
ensure the assay quality. If the control results were outside
of the acceptable limits determined by the assay method
validation, the run was rejected, and all samples on the
same gel were repeated.Anthropometric and lifestyle exposures
Baseline smoking status (current use yes/no) and race-
ethnicity were obtained through self-reported question-
naire. Height (cm) and weight (kg) of participants, wearing
light clothing and without shoes, was measured with
stadiometers and calibrated balance-beam scales, respect-
ively. BMI was calculated as weight in kilograms divided
by the square of height in meters. Waist circumference
(cm) was measured with a non-stretchable tape at the end
of a normal expiration, at the smallest horizontal circum-
ference between the ribs and iliac crest. Blood pressure
was measured in the right arm in the seated position, after
at least a 5 minute rest, and was averaged across two
readings.Subclinical atherosclerosis measures
Carotid artery intima-media thickness (CIMT) was
measured from high resolution B-mode ultrasound
images obtained with a 7.5 MHz transducer at both the
screening and baseline KEEPS visits. Carotid artery
images were acquired at each study center by certified
ultrasound technicians trained at the core CIMT imaging
and reading center (PI: Dr. Howard Hodis, USC) to
perform standardized image acquisition. Image acquisi-
tion was optimized for minimal measurement variability
(coefficient of variation <2%) using methodology devel-
oped specifically for reproducible longitudinal imaging
employing internal anatomical structural probe angula-
tion techniques including vessel stacking, baseline image
matching, electrocardiographic gating, and individualized
instrumentation conditions (Patents 2005, 2006, 2011)
[19]. All images were analyzed by an experienced investi-
gator at the core CIMT imaging and reading center
using in-house developed computerized automated edge
detection software employing subpixel interpolation
(Patents 2005, 2006, 2011) [19]. CIMT values used in the
current analyses represent an average of the screening
and baseline CIMT measurements.Each participant underwent non-enhanced cardiac com-
puted tomography (CT) scans for assessment of coronary
atherosclerosis. Scans were acquired either via electron
beam CT (GE/Imatron, Inc.), or via multidetector CT
using either a General Electric helical scanner or a Sie-
mens or Phillips multi-slice scanner (minimum require-
ment 4 detector heads). Comparability among centers was
assured by regular calibration using a standard phantom.
The scans were obtained during a single breath hold at
end inspiration to reduce motion artifacts and improve
image quality of the coronary arteries. Coronary calcium
was defined as a plaque of at least 3 contiguous pixels
(area 1.02 mm2) with a density of >130 Hounsfield units.
The individual lesion score was calculated by multiplying
the lesion area by a density factor derived from the
maximal Hounsfield unit within this area, as described by
Agatston et al. [20]. A total CAC score was determined
by summing the individual lesion scores from each of
4 anatomic sites (left main, left anterior descending,
circumflex, and right coronary). A single experienced
investigator, blinded to the subject identity, interpreted
all the scans using commercially available software
(TeraRecon, Foster City, CA).
Statistical analyses
Mean (standard deviation), median (interquartile range),
or n (%) were tabulated for demographic, behavioral, and
laboratory characteristics by quartiles of RBP4. Differences
in the distributions of these variables across RBP4 quartiles
were calculated by the Chi-Square test for categorical
variables, ANOVA for normally distributed continuous
variables, and the Kruskal-Wallis test for non-normally
distributed continuous variables. Following this, partial
Spearman correlation coefficients were calculated for asso-
ciations between RBP4 and cardiometabolic risk factors
and CIMT, adjusted for age, race (white vs. non-white), and
current smoking. To assess associations between RBP4 and
CAC, multivariable adjusted logistic regression was used to
calculate odds ratios of CAC score >0 across quartiles of
RBP4, as well as treating RBP4 as a continuous variable
after log-transformation, adjusted for age, race, and current
smoking, and again after additional adjustment for triglyc-
erides. To ensure that residual confounding by smoking
was not influencing associations, sensitivity analyses were
carried out excluding current smokers from regression
analyses.
Results
The mean age of study participants was 52.9 (± 2.6)
years. Demographic and laboratory characteristics strat-
ified by quartiles of RBP4 are presented in Table 1. The
mean age, prevalence of current smoking, proportion
of non-White participants, and levels of cardiometabolic
risk factors did not differ across quartiles of RBP4. With
Table 1 Study Characteristics by Quartiles of RBP4
RBP4 Quartile, μg/mL
≤36.9 37.0-49.0 49.1-61.4 ≥61.5 P-value**
Age, years 52.7 (0.2) 53.1 (0.2) 52.7 (0.2) 53.1 (0.2) 0.33
% Current Smokers 8.0% 6.7% 6.8% 4.5% 0.21
% Non-White Race 29.6% 21.9% 21.5% 21.4% 0.08
BMI, kg/m2 26.1 (0.3) 26.2 (0.3) 26.3 (0.3) 26.4 (0.3) 0.49
Waist Circumference, cm* 82.0 (16.5) 82.7 (15.2) 83.8 (18.0) 85.8 (17.0) 0.42
Systolic Blood Pressure, mmHg 118.1 (1.1) 119.4 (1.1) 117.2 (1.1) 120.3 (1.2) 0.38
Diastolic Blood Pressure, mmHg 74.7 (0.7) 75.3 (0.7) 73.8 (0.6) 75.6 (0.7) 0.66
HDL-C, mmol/L 1.71 (0.03) 1.68 (0.03) 1.66 (0.04) 1.71 (0.04) 0.94
Triglycerides, mmol/L* 0.82 (0.53) 0.86 (0.53) 0.94 (0.53) 0.92 (0.57) 0.09
Glucose, mmol/L 4.95 (0.04) 4.93 (0.04) 4.96 (0.04) 4.94 (0.04) 0.94
Insulin, pmol/L* 27.8 (31.9) 27.8 (36.1) 28.5 (34.7) 34.0 (43.8) 0.23
C-reactive Protein, mg/dL* 0.8 (1.9) 1.2 (2.2) 1.1 (2.1) 0.9 (2.2) 0.14
Carotid IMT, mm* 0.71 (0.11) 0.70 (0.11) 0.72 (0.10) 0.72 (0.11) 0.52
Values are mean (standard deviation) unless otherwise indicated. *median (interquartile range).
**P-value from Chi-Square test for categorical variables, ANOVA for normally distributed variables, and from the Kruskal-Wallis Test for non-normally distributed variables.
RBP4 retinol-binding protein 4; BMI body mass index; IMT intima-media thickness.
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ciations of cardiometabolic risk factors and RBP4
remained null (all P> 0.05) after multivariable adjustment
for age, race-ethnicity, and smoking status (Table 2).
CIMT was similarly not associated with RBP4 either prior
to or after multivariable adjustment (Tables 1 and 2). The
prevalence of CAC score>0 was similar in the 1st, 3rd,
and 4th quartiles of RBP4, but appeared lower in the 2nd
tertile (Figure 1), though this difference was not statisti-
cally significant (P-value for chi-square test = 0.15). To
further explore the possibility of a curvilinear association,
multivariable-adjusted logistic regression models for CAC
were initially performed with the 1st RBP4 quartile as the
reference category (Table 3, Model 1), but were repeated
utilizing the 2nd RBP4 quartile as the reference category
(Table 3, Model 2). When using the 1st RBP4 quartile as
the reference, there was a statistically significant 51% lower
odds of CAC with RBP4 levels in the range of 37 to
49 mg/mL in comparison to the lowest RBP4 levels
(≤36.9 mg/mL) after adjustment for age, race, and current
smoking (Table 3, Model 1). However, in comparison to
the first quartile, the 3rd and 4th RBP4 quartiles were not
significantly associated with CAC. When using the 2nd
RBP4 quartile as the reference category (37.0-49.0 mg/mL)Table 2 Partial* Spearman Correlation Coefficients for Associa
Carotid IMT
BMI Waist Circum. HDL-C Triglycerides
r 0.02 0.04 −0.0006 0.10
p-value 0.55 0.26 0.99 0.01
*Adjusted for age, race-ethnicity, and current smoking.
RBP4 retinol-binding protein 4; BMI body mass index; IMT intima-media thickness.(Table 3, Model 2), a curvilinear relationship between RBP4
quartiles and CAC was suggested, with both lower and
higher RBP4 quartiles associated with higher odds of CAC.
However, despite this pattern, a squared RBP4 term tested
in the context of logistic regression was not statistically sig-
nificant (p=0.10). There was no evidence of a linear associ-
ation between RBP4 and the prevalence of CAC score >0
(Table 3, Model 3). Given the statistically significant
association between triglycerides and RBP4, CAC ana-
lyses were additionally adjusted for triglycerides. The
magnitude of odds ratios was very similar to models
without inclusion of triglycerides (ORs [95% CIs]: 2.11
[1.08-4.11], 1.93 [0.99-3.79], 1.59 [0.79-3.16] for the 1st,
3rd, and 4th RBP4 quartiles, respectively, vs. the 2nd,
adjusted for age, race, current smoking, and triglycerides).
Due to the curvilinearity suggested by the RBP4-CAC
relationship, logistic regression analyses tabulating odds
ratios of the top tertile of each cardiometabolic risk
factor associated with being in the 2nd RBP4 quartile vs.
the 1st, 3rd, and 4th were carried out similar to Model 2
in Table 3. Curvilinearity was not suggested for any of
the cardiometabolic risk factors examined or CIMT.
Sensitivity analyses excluding current smokers from
regression models resulted in nearly identical oddstions between RBP4 and Cardiometabolic Factors and
Glucose Insulin C-Reactive Protein Carotid IMT
0.002 0.06 0.03 0.03
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Figure 1 Prevalence (%) of CAC score > 0 by RBP4 Quartiles.
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current smokers.Discussion
Among these healthy, recently postmenopausal women,
higher RBP4 levels were weakly associated with greater
triglyceride levels, and both low and high RBP4 levels
were associated with approximately twice the odds of
the presence of CAC. No associations were observed
between RBP4 levels and other cardiometabolic risk
factors or CIMT.
RBP4 has long-been known to be released by the liver,
but recently, it has been shown that approximately 15% of
circulating RBP4 levels results from adipose tissue RBP4
secretion [6]. RBP4 down-regulates GLUT4 [6,7], the
insulin-activated glucose transporter responsible for trans-
location of glucose into both muscle and fat cells [6], andTable 3 Adjusted* Odds Ratios of CAC > 0 associated
with RBP4
Odds Ratio 95% CI
Model 1
RBP4 Quartiles (μg/mL)
≤36.9 (Reference) 1.00 ——
37.0-49.0 0.49 0.25-0.95
49.1-61.4 0.95 0.54-1.69
≥61.5 0.78 0.43-1.42
Model 2
RBP4 Quartiles (μg/mL)
≤36.9 2.10 1.07-4.09
37.0-49.0 (Reference) 1.00 ——
49.1-61.4 2.00 1.02-3.92
≥61.5 1.64 0.82-3.27
Model 3
Per μg/mL increase in log-RBP4 1.00 0.55-1.81
*All three models adjusted for age, race-ethnicity, and current smoking.
RBP4 retinol-binding protein 4.has also recently been shown to induce expression and
secretion of pro-inflammatory cytokines in primary human
macrophages known to induce insulin resistance [21]. In
humans, circulating RBP4 levels were found to be highly
negatively correlated with levels of insulin sensitivity, and
to be increased with obesity and in those with type 2
diabetes [6-14]. However, discrepant results from other
studies have questioned these associations, failing to
demonstrate associations with either obesity or indicators
of glucose homeostasis [9,15-17]. Results from the present
study also found no association between RBP4 and BMI,
waist circumference, glucose, or insulin levels. In addition
to possible measurement error resulting from use of
immunoassay in prior studies [18], a potential contributing
factor to the discrepant literature is that the relationship
between RBP4 and insulin resistance may be stronger in
younger individuals than older [22], possibly from changes
in body fat distribution with age.
Retinoids have been known to affect the expression of
several genes involved in triglyceride metabolism, includ-
ing regulators of apo C-III production, hepatic and gastro-
intestinal triglyceride production and secretion, and
beta-oxidation of fatty acids [23]. As such, similar to our
finding of higher triglyceride levels with higher RBP4
values, prior studies have shown that RBP4 is correlated
with serum triglycerides [13,14,22,24-27]. In addition,
although prior studies have often documented associations
between RBP4 and other cardiometabolic risk factors
in addition to triglycerides, some studies support our
findings of an association with triglycerides, only. In a
cross-sectional analysis of 308 non-diabetic patients with
hypertension, Shim et al. discovered associations between
RBP4 and indices of metabolic syndrome to be null, with
the exception of triglycerides, which yielded a significant
positive correlation (r = 0.25, P< 0.001) [28]. A study of
473 subjects with normal glucose tolerance revealed
similar results, with RBP4 positively correlated with trigly-
cerides (r = 0.10, P< 0.001) but not with other cardiometa-
bolic risk factors [29]. The present study extends these
findings by demonstrating an association between RBP4
and triglycerides, but not other cardiometabolic risk fac-
tors, in a population of healthy, midlife women, utilizing
the gold standard RBP4 measurement methodology.
The association between RBP4 and CIMT, a measure
of systemic atherosclerosis, has been investigated in only
a few studies, and as with relationships between RBP4
levels and obesity, insulin resistance, and other CVD risk
markers, results conflict. Despite recent data suggesting
that increases in fasting plasma glucose even within the
normal range are associated with worse arterial stiffness
levels [30], reported results suggest not only positive
associations between RBP4, which down-regulates the
glucose transporter GLUT-4, and CIMT, but also inverse
associations, and similar to our results, null associations
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here in healthy midlife women have also been reported
in type 2 diabetes patients, both for CIMT and for
other measures of peripheral subclinical disease includ-
ing ankle-brachial index and carotid/femoral echography
[14,34].
In contrast to our findings with CIMT and to earlier
findings noted above with ankle-brachial index, we
observed a significantly higher odds of the presence of
CAC in women with both low and high RBP4 levels
compared to women with moderate (2nd RBP4 quartile)
RBP4 levels. The odds of having a CAC score> 0 in
women in either the 1st or 3rd quartiles of RBP4 were
approximately 2 times higher than that among women
with RBP4 levels in the 2nd quartile. Similarly, women in
the 4th RBP4 quartile had a non-significantly 64% higher
odds of having a CAC score> 0 compared to women in
the 2nd RBP4 quartile. To our knowledge, this is the first
investigation to assess the association of RBP4 with the
presence of CAC. These findings require replication in
future studies and need to be interpreted with consider-
able caution given the lack of a significant squared RBP4
term in regression analyses. Caution is especially indicated
given the relatively small number of women with CAC
score> 0 in the current study (n= 93 overall, and n= 15 in
the 2nd RBP4 quartile, the quartile which appeared to have
a lower CAC prevalence), and the null association with
CIMT, an alternative measure of atherosclerosis. Had
RBP4 levels been associated with measures of glucose
homeostasis as in certain prior studies, a u-shaped associ-
ation with coronary atherosclerosis might be supported
given the heightened CVD death not only with hypergly-
cemia, but also potentially with hypoglycemia, as sug-
gested by the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial results [35]. However, in the
current study, RBP4 levels were not associated with
glucose, insulin, BMI, or waist circumference. Should our
CAC findings be replicated in a future study, they would be
supported not only by one published study finding lower
median RBP4 levels in patients with CAD (27.8 μg/mL) vs.
controls (29.8 μg/mL),[36] but also by published data
suggesting differential associations of CAC vs. CIMT with
CVD risk factors and CVD events [37,38].
Some limitations of this study must be taken into con-
sideration. The design of this study was cross-sectional, so
the results do not imply causality. Our study sample also
included only healthy, recently menopausal women.
Therefore, our results may not be applicable to an older
population with greater prevalence of atherosclerosis.
Additionally, glucose and lipids were obtained from blood
collected during screening, while insulin, CRP and RBP4
were obtained from blood collected at the baseline
randomization examination. Therefore, we were unable
to calculate insulin resistance via the homeostasis modelassessment (HOMA-IR), and a bias towards the null was
introduced for associations between RBP4 and lipids and
glucose. However, insulin levels, despite being measured
at the same alternate visit as RBP4, showed moderate to
strong associations with lipids and glucose (Spearman
correlation coefficient of −0.4 with HDL, 0.4 with trigly-
cerides, and 0.3 with glucose; all P< 0.001) but a null asso-
ciation with RBP4 (Spearman correlation coefficient = 0.06;
P=0.10), suggesting that null associations between
RBP4 and HDL and glucose were not a result of the meas-
urement schedule.
The primary strength of this study involves the method
of RBP4 detection. The quantitative western blot method-
ology that we have chosen has been cited as the gold-
standard for RBP4 determination [18], and utilizes the
full-length RBP4 protein and monoclonal antibody specific
for full-length RBP4 protein, greatly increasing validity
compared to numerous prior investigations utilizing
immunoassay. This method was employed despite the
large sample size of the KEEPS trial, making this the
largest investigation to utilize quantitative western blot
methodology for assessment of these relationships. In
addition, the health of the KEEPS participants enabled
assessment of the associations between RBP4 and CVD-
related parameters prior to disease expression.
Conclusions
These analyses in healthy, recently postmenopausal
women suggest that higher RBP4 levels are weakly asso-
ciated with elevations in triglycerides, and that both low
and high RBP4 levels may be associated with subclinical
coronary atherosclerosis. Given the caution with which
the coronary atherosclerosis results should be viewed, our
current results in healthy midlife women only weakly
support a role for RBP4 homeostasis in cardiometabolic
abnormalities and cardiovascular disease. However, future
studies should attempt to replicate our CAC findings. If
successful, RBP4 may end up warranting examination as a
potential target of interventions to reduce CVD risk.
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